ライフサイエンスコーパス: renal transplant recipient

1 n and disease are major complications in the renal transplant recipient.

2 e comparable to those previously reported in renal transplant recipients.

3 transplant immune surveillance for pediatric renal transplant recipients.

4 ally in the increasing population of elderly renal transplant recipients.

5 ogression of kidney failure and mortality in renal transplant recipients.

6 mmunohistochemically TAg-positive UCs in two renal transplant recipients.

7 ld and clinical utility of WES for pediatric renal transplant recipients.

8 and OGTT were performed in 1,619 nondiabetic renal transplant recipients.

9 alent to the original formulation in elderly renal transplant recipients.

10 curs in 16% to 20% of low-risk, CMV-positive renal transplant recipients.

11 onitoring in a large, multi-ethnic cohort of renal transplant recipients.

12 and cytokine plasma levels in 30, potential renal transplant recipients.

13 We studied a cohort of 570 consecutive renal transplant recipients.

14 -INT was evaluated in 2055 biopsies from 775 renal transplant recipients.

15 n unfavorable cardiovascular risk profile in renal transplant recipients.

16 rm renal function and the overall outcome of renal transplant recipients.

17 rt study of 80 cases occurring in 4189 adult renal transplant recipients.

18 inuria is associated with poorer outcomes in renal transplant recipients.

19 obulin (rATG; Thymoglobulin) in living donor renal transplant recipients.

20 e incidence and severity of CMV infection in renal transplant recipients.

21 ides management and outcome of BK viremia in renal transplant recipients.

22 d with a triple immunosuppressive therapy in renal transplant recipients.

23 pact on peri- and posttransplant measures in renal transplant recipients.

24 nown about its effects on the bone health of renal transplant recipients.

25 to attenuate bone loss can be recommended in renal transplant recipients.

26 o potentiate DSA removal by PE in sensitized renal transplant recipients.

27 tion of, pretransplant dialysis in pediatric renal transplant recipients.

28 rapid DSA elimination in early acute AMR in renal transplant recipients.

29 in diminished patient and graft survivals in renal transplant recipients.

30 with mortality has not been well studied in renal transplant recipients.

31 te set of genes for wider-scale screening of renal transplant recipients.

32 s, and chronic allograft injury in pediatric renal transplant recipients.

33 mplications occur in almost 1 in 5 pediatric renal transplant recipients.

34 mmunosuppressive regimen in HLA-identical LD renal transplant recipients.

35 gnificantly associated with DGF in pediatric renal transplant recipients.

36 s, correlates with delayed graft function in renal transplant recipients.

37 genic factor of urothelial carcinoma (UC) in renal transplant recipients.

38 t-line Pneumocystis pneumonia prophylaxis in renal transplant recipients.

39 A antibodies (dnDSA) may cause graft loss in renal transplant recipients.

40 nt in the patient with JCPyVAN and in stable renal transplant recipients.

41 ependent of plasma HDL cholesterol levels in renal transplant recipients.

42 rence in this cohort of long-term, high-risk renal transplant recipients.

43 ed with better patient and graft survival in renal transplant recipients.

44 ffness, oxidative stress, or inflammation in renal transplant recipients.

45 fness, oxidative stress, and inflammation in renal transplant recipients.

46 cept in 29 human leukocyte antigen-immunized renal-transplant recipients.

47 allowing early glucocorticoid withdrawal in renal-transplant recipients.

48 ion, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipien

49 Twenty renal transplant recipients (10 rituximab-treated, 10 pl

50 Of the 85,873 renal transplant recipients, 1062 patients had amputatio

51 We analyzed T cells from 57 living-donor renal transplant recipients (12 reactive and 45 quiescen

52 By using 83 unique pediatric renal transplant recipients, 126 protocol, serial, postt

53 of AR and after AR treatment in 35 pediatric renal transplant recipients: 17 patients with AR who rec

54 Of the 6,317 renal transplant recipients, 346 (5.5%) received OLD kid

55 t study and case-control study in 50 de novo renal transplant recipients, 50 chronic kidney disease (

56 We selected 2064 renal transplant recipients: 688 with a known cardiovasc

57 We aimed to evaluate this risk score in renal transplant recipients, a population with heightene

58 , we systematically analyzed HDL from stable renal transplant recipients, according to graft function

59 nt Registry, primary live and deceased donor renal transplant recipients aged 18 years or older betwe

60 To test this hypothesis, 32 renal transplant recipients aged 55 years and older with

61 ed States Renal Data System data for primary renal transplant recipients (ages 0-21 years, transplant

62 ed 12-hour everolimus (EVL) PK in 16 elderly renal transplant recipients (all whites; 10 men; mean ag

63 pheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontransplant contro

64 Eighteen nondiabetic renal transplant recipients and 20 healthy control subje

65 010 and 2011) influenza vaccine in 23 stable renal transplant recipients and 22 healthy controls.

66 velopment and long-term graft function in 16 renal transplant recipients and 32 age- and gender-match

67 t failure, but large-scale data in pediatric renal transplant recipients and a comprehensive analysis

68 l carcinoma is the most common malignancy in renal transplant recipients and a major cause of morbidi

69 We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with T

70 easured routinely for diagnostic purposes in renal transplant recipients and are associated with anti

71 BKPyV is known to cause severe morbidity in renal transplant recipients and can lead to graft reject

72 This study evaluated 664 renal transplant recipients and correlated HLA-DR/DQ sin

73 Renal transplant recipients and dialysis patients were e

74 These data will further inform prospective renal transplant recipients and donors during pretranspl

75 ffects a significant proportion of pediatric renal transplant recipients and is associated with uniqu

76 on accounts for around half of all pediatric renal transplant recipients and results in improved rena

77 reshold value likely needs to be lowered for renal transplant recipients and supports continued use o

78 sured in a longitudinal cohort of 699 stable renal transplant recipients and the associations of T50

79 cells obtained from a new cohort of tolerant renal transplant recipients and those from age- and sex-

80 k factors for visceral leishmaniasis (VL) in renal transplant recipients and to analyze the impacts o

81 entify clinically significant de novo DSA in renal transplant recipients and to define the properties

82 ant candidates, 8.02 (95% CI, 7.29-8.83) for renal transplant recipients, and 13.7 (95% CI, 11.5-16.3

83 ed in 2,851 Caucasian and 570 Afro-Caribbean renal transplant recipients, and in 236 transplant recip

84 CPyV) is reactivated in approximately 20% of renal transplant recipients, and it may rarely cause JCP

85 is a risk factor for acute rejection (AR) in renal transplant recipients, and KDIGO guidelines sugges

86 ct development of squamous cell carcinoma in renal transplant recipients, and undertook a prospective

87 Approximately only 50% of renal transplant recipients are alive at 10 years due to

88 or the prevention of rejection in sensitized renal transplant recipients are not well established.

89 In Brazil, most renal transplant recipients are on social security benef

90 reported cohort to our knowledge of tolerant renal transplant recipients, as defined by stable graft

91 differentiated CD8(+) T cells would identify renal transplant recipients at elevated SCC risk.

92 finding could help in the identification of renal transplant recipients at high risk of this cancer,

93 In a population of 48 stable renal transplant recipients at least 6 months from time

94 approximately 800 patients in the cohort of renal transplant recipients at our institution, 15 subje

95 lin (TMG) and basiliximab (BAS) induction in renal transplant recipients at risk for delayed graft fu

96 d tomography scans of the tibia in pediatric renal transplant recipients at transplantation and 3, 6,

97 and treatment strategies for dyslipidemia in renal transplant recipients based on a literature review

98 e and plasma samples were collected from 112 renal transplant recipients before and after transplanta

99 ogic and infection-related parameters in 499 renal transplant recipients between 1 month and 33 years

100 ystems patient and claims data for all adult renal transplant recipients between 2000 and 2010 with c

101 Renal transplant recipients beyond 1 month posttransplan

102 be the effects of AL induction therapy on AA renal transplant recipients beyond the first posttranspl

103 Endothelial dysfunction is prevalent in renal transplant recipients, but it is uncertain if ther

104 isease remains the leading cause of death in renal transplant recipients, but the underlying causativ

105 that with time the large majority of stable renal transplant recipients can be safely reduced to dua

106 Melanoma risk factors and incidence in renal transplant recipients can inform decision making f

107 based immunosuppressive treatment in de novo renal transplant recipients caused marginal changes in L

108 We randomly assigned 70 renal transplant recipients (CMV-seropositive recipient

109 SCCs (13) from renal transplant recipients displayed the same telomere

110 sfusions are generally avoided for potential renal transplant recipients due to risk of human leukocy

111 tation of PTTB and may show delayed onset in renal transplant recipients due to the use of lower dose

112 this pooled data analysis in more than 2000 renal transplant recipients, EVR versus MPA resulted in

113 Majority of renal transplant recipients experienced stable or improv

114 Few studies have examined nondiabetic renal transplant recipients for occult defects in insuli

115 lled study using C1-INH in highly sensitized renal transplant recipients for prevention of AMR.

116 (EBV) DNAemia by monthly PCR in 55 pediatric renal transplant recipients for the first 2 years after

117 arge national data registry used a cohort of renal transplant recipients from the United States Renal

118 cruited 640 consecutive incident nondiabetic renal transplant recipients from three academic centers

119 Data on 2004 renal transplant recipients from three EVR studies were

120 ing efficacy and safety of converting stable renal transplant recipients from twice-daily tacrolimus

121 Nearly one third of pediatric renal transplant recipients had a genetic cause of their

122 Fifty-one (69%) renal transplant recipients had fDGF, of which 14 experi

123 Renal transplant recipients had greater risk of developi

124 Nondiabetic renal transplant recipients had lower FPIR than controls

125 eline, compared with reference participants, renal transplant recipients had significantly lower mean

126 ugh the proportion of elderly patients among renal transplant recipients has increased, pharmacokinet

127 Research in renal transplant recipients has suggested that pancreati

128 There is evidence that renal transplant recipients have accelerated atheroscler

129 Renal transplant recipients have an increased risk of no

130 Renal transplant recipients have an increased risk to de

131 tein-Barr virus (EBV) infection in pediatric renal transplant recipients have been characterized insu

132 We analyzed a prospective cohort of renal transplant recipients having routine EBV PCR surve

133 HLA sensitization in potential renal transplant recipients hinders opportunities of rec

134 A previous GWAS performed in 300 renal transplant recipients identified two SNPs (rs38113

135 A renal transplant recipient in her 60s presented with a h

136 ective population-based cohort study of 5970 renal transplant recipients in Australia registered on t

137 We describe the results of 11 ABOi pediatric renal transplant recipients in the 2 largest centers in

138 or the progression of glucose intolerance in renal transplant recipients in the late posttransplant p

139 Retrospective review of all renal transplant recipients in the United Network for Or

140 tive cohort of 41,705 adult Medicare primary renal transplant recipients in the United States Renal D

141 This study puts focus on renal transplant recipients in their 80th year or longer

142 In moderately sensitized deceased donor renal transplant recipients, induction with ATG is assoc

143 In conclusion, among renal transplant recipients, infection with one polyomav

144 A retrospective study was conducted in 379 renal transplant recipients initiated on EC-MPS or MMF t

145 Hypertension in renal transplant recipients is common and ranges from 50

146 dity associated with malignancy in long-term renal transplant recipients is due to cutaneous squamous

147 BKV) infection and associated nephropathy in renal transplant recipients is not clearly understood.

148 ment of hepatitis C virus (HCV) infection in renal transplant recipients is possible, but limited dat

149 In stable renal transplant recipients, late CNI withdrawal from a

150 living with cats increased the risk of VL in renal transplant recipients living in VL endemic areas.

151 In renal transplant recipients, mammalian target of rapamyc

152 ave been reported in ABO-incompatible (ABOi) renal transplant recipients managed solely with antibody

153 use of hereditary and acquired risk factors, renal transplant recipients manifest features of a chron

154 sion in patients on CNI therapy, most stable renal transplant recipients may benefit from late CNI wi

155 A, after B-lymphocyte depletion treatment in renal transplant recipients may contribute to the effica

156 Thus, early testing of urine samples from renal transplant recipients may identify those at risk f

157 sttransplant serum samples from 18 pediatric renal transplant recipients, measured against 5,056 uniq

158 Thirteen pediatric renal transplant recipients meeting defined high-risk cr

159 etabolism in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttrans

160 epidemiology in a large cohort of pediatric renal transplant recipients (n = 242) and assessed the i

161 Renal transplant recipients (n=37) were randomized to ea

162 mortality, and graft failure in a cohort of renal transplant recipients (n=495, median follow-up 7.0

163 a single-center, prospective cohort study of renal transplant recipients (N=81), urinary clusterin wa

164 ejection (BPAR) in 216 moderately sensitized renal transplant recipients (negative flow crossmatch an

165 t a rare survival case of isolated GITB in a renal transplant recipient, occurring seven years after

166 Renal transplant recipients of African American race had

167 ) formulation with the original (Prograf) in renal transplant recipients older than 60 years.

168 trolled withdrawal study enrolled 177 stable renal transplant recipients on maintenance CNI-based imm

169 A total of 119 stable renal transplant recipients on triple regimen with stero

170 We retrospectively collected data on all renal transplant recipients over a 10-year period.

171 Homoarginine was measured in 829 renal transplant recipients participating in the placebo

172 drawal, from a triple-drug regimen in stable renal transplant recipients, prevented progressive deter

173 pathy (BKVN), affects 5% to 16% of pediatric renal transplant recipients (PRTR).

174 phase IIIb, open-label trial of 833 de novo renal transplant recipients randomized to everolimus, ta

175 This retrospective study of 242 adult renal transplant recipients receiving rATG induction and

176 h acute cellular rejection (ACR) in 43 adult renal transplant recipients receiving steroid-free tacro

177 estimated glomerular filtration rate, and 23 renal transplant recipients referred for parathyroidecto

178 Renal transplant recipients regularly fail to take their

179 Notably, BP treatment goals for renal transplant recipients remain an enigma because the

180 apy for Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug react

181 proteinuria, diabetes, or CKD stages 1-4 or renal transplant recipients reporting >/=10 ESRD events

182 Among renal transplant recipients, risk factors included male

183 We hypothesized that a renal transplant recipient (RTR) carrying the homozygous

184 intake, with graft failure and mortality in renal transplant recipients (RTR) and potential effect m

185 e potential role of SDMA as a risk marker in renal transplant recipients (RTR) has not been investiga

186 igh-risk, donor-positive/recipient-negative, renal transplant recipients (RTR).

187 rparathyroidism is reported in 10% to 66% of renal transplant recipients (RTR).

188 g is a risk factor for poor late outcomes in renal transplant recipients (RTR).

189 nd its impact on renal function in pediatric renal transplant recipients (RTR).

190 k for future development of graft failure in renal transplant recipients (RTR).

191 tabolites with cardiometabolic parameters in renal transplant recipients (RTRs) and analyzed their pr

192 f pyridoxal 5'-phosphate (PLP) are common in renal transplant recipients (RTRs) and confer increased

193 Eighteen renal transplant recipients (RTRs) developed Pneumocysti

194 Renal transplant recipients (RTRs) have commonly been ur

195 Renal transplant recipients (RTRs) have increased cardio

196 Renal transplant recipients (RTRs) have increased cardio

197 ors (ACE-i) on the cardiovascular outcome of renal transplant recipients (RTRs) receiving calcineurin

198 cancer (NMSC) is substantially higher among renal transplant recipients (RTRs) than in the general p

199 essing left ventricular hypertrophy (LVH) in renal transplant recipients (RTRs) with chronic allograf

200 to modulate cardiovascular complications in renal transplant recipients (RTRs), and a relationship b

201 Renal transplant recipients (RTRs), as all immunosuppres

202 on viral infections that affect up to 10% of renal transplant recipients (RTRs), causing allograft dy

203 In renal transplant recipients (RTRs), new-onset diabetes a

204 Arterial hypertension (HT) is common in renal transplant recipients (RTRs).

205 re cardiovascular morbidity and mortality in renal transplant recipients (RTRs).

206 centrations of pyridoxal-5-phospate (PLP) in renal transplant recipients (RTRs).

207 s, 16 outbreaks occurred, including 13 among renal transplant recipients (RTRs).

208 ssociated with an increased risk of death in renal transplant recipients (RTRs).

209 ral blood monocyte cells and CD3+ T cells of renal transplant recipients (RTX) receiving tacrolimus (

210 Our data indicate that elderly renal transplant recipients starting EVL 1 month after t

211 compartments from 20 HCMV-infected patients (renal transplant recipients, stem cell transplant recipi

212 This review included 369 renal transplant recipients tested for BK virus at seria

213 carcinoma development in long-term, at-risk renal transplant recipients than previously identified c

214 was tested on >1000 samples from a cohort of renal transplant recipients to assess its performance in

215 cept clinical trial, we randomly assigned 50 renal transplant recipients to immediate-postoperative i

216 o 24 months posttransplant in solitary adult renal transplant recipients transplanted between 2003 an

217 rospective cohort of 40,821 Medicare primary renal transplant recipients transplanted from January 1,

218 pective cohort study of 2749 adult Norwegian renal transplant recipients, transplanted between 1999 a

219 We studied renal transplant recipients treated with prednisolone, c

220 We performed a retrospective analysis of renal transplant recipients treated with rapamycin from

221 d pressure monitoring (ABPM) in 33 pediatric renal transplant recipients (TXP), aged 8 to 19 years, m

222 , point to the need for careful follow-up of renal transplant recipients undergoing intravitreal ther

223 We recommend that in renal transplant recipients undergoing therapy with intr

224 an leukocyte antigen-mismatched living donor renal transplant recipients underwent low-intensity cond

225 retrospective study in which 76 non-diabetic renal transplant recipients underwent oral glucose toler

226 d standard (iohexol plasma clearance) in 193 renal transplant recipients using concordance correlatio

227 (NODM) after kidney transplant in pediatric renal transplant recipients using Organ Procurement Tran

228 pared cancer incidence in PKD versus non-PKD renal transplant recipients using Poisson regression, an

229 Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CK

230 tcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CKD group or

231 ulations, plasma neopterin, and cytokines in renal transplant recipients was investigated in this stu

232 ation-based, nationwide cohort of first-time renal transplant recipients was matched by age and sex w

233 group, comparative study in primary de novo renal transplant recipients was planned for 48 months bu

234 From 1988 consecutive renal transplant recipients, we analyzed 179 patients un

235 e maintenance immunosuppression in pediatric renal transplant recipients, we enrolled 35 participants

236 invasive squamous cell carcinomas (SCCs) in renal transplant recipients, we investigated whether con

237 ousand three hundred seventy-eight pediatric renal transplant recipients were analyzed; 804 (58%) rec

238 Renal transplant recipients were classified as never, fo

239 The significant risk factors for VL in renal transplant recipients were cytomegalovirus infecti

240 Renal transplant recipients were included if they were a

241 Five hundred seventy-seven consecutive renal transplant recipients were included.

242 A total of 5983 renal transplant recipients were included.

243 Between August 2009 and October 2010, 40 renal transplant recipients were prospectively included

244 hundred twenty-three live or deceased donor renal transplant recipients were randomized 2:1 to recei

245 Renal transplant recipients were randomized to receive e

246 Eighty renal transplant recipients were randomized, and 78 were

247 Three hundred seventy-nine asymptomatic renal transplant recipients were recruited between June

248 comparing fluvastatin with placebo in stable renal transplant recipients, were genotyped for all SNPs

249 ction against early acute rejection in black renal transplant recipients, whereas sensitized patients

250 reg cells as an adoptive cellular therapy in renal transplant recipients who are using everolimus (EV

251 etermine risk factors and characteristics of renal transplant recipients who develop melanoma.

252 Clinical data of all female renal transplant recipients who developed anogenital mal

253 We retrospectively identified 59 renal transplant recipients who developed dnDSA and had

254 We report 2 cases of renal transplant recipients who developed significant al

255 Renal transplant recipients who experience delayed graft

256 Adult renal transplant recipients who had symptomatic chronic

257 The proportion of renal transplant recipients who met the composite endpoi

258 ulating anti-PLA2R antibodies in a cohort of renal transplant recipients who prospectively developed

259 cell depletion and recovery among pediatric renal transplant recipients who receive alemtuzumab indu

260 th a functioning graft (DWFG) is affected in renal transplant recipients who receive prophylaxis for

261 There was a significant increase in renal transplant recipients who were HIV seropositive wh

262 s a substudy of a randomized trial in stable renal transplant recipients who were on a triple CNI-bas

263 , we describe the case of a 63-year-old male renal transplant recipient with a remote history of pulm

264 We report our experience treating 43 renal transplant recipients with 4 different DAA regimen

265 A cohort of 596 renal transplant recipients with 50,011 serial tacrolimu

266 sease (CVD) is the leading cause of death in renal transplant recipients with a functioning allograft

267 ective randomized trial to determine whether renal transplant recipients with a positive CMV serostat

268 Renal transplant recipients with acute AMR were treated

269 Twelve renal transplant recipients with aHUS-related end-stage

270 ted vasculitis, as well as in some groups of renal transplant recipients with alloimmune graft damage

271 57 renal transplant recipients with and 53 without previous

272 Renal transplant recipients with and without previous sq

273 In a 2-year randomized controlled trial, 155 renal transplant recipients with at least one biopsy-con

274 Graft loss occurs in up to 60% of renal transplant recipients with BKN.

275 In renal transplant recipients with CKD stages 4 to 5T, pat

276 Renal transplant recipients with de novo DSA (dDSA) expe

277 Retrospective cohort study evaluating renal transplant recipients with first AMR episodes trea

278 Eighty-one renal transplant recipients with FMF-associated AA amylo

279 pective, double-blind, parallel-group trial, renal transplant recipients with GI symptoms receiving M

280 dies evaluating treatment with cinacalcet in renal transplant recipients with hyperparathyroidism.

281 es from 1 patient with JCPyVAN and 20 stable renal transplant recipients with JCPyV viruria was attem

282 clusion criteria permitting analysis of 3312 renal transplant recipients with median follow-up of 12

283 Renal transplant recipients with otherwise unexplainable

284 However, it is not known whether renal transplant recipients with PKD have an increased r

285 infection has been reported in 10% to 60% of renal transplant recipients with progression to BK nephr

286 l but not death-censored renal graft loss in renal transplant recipients with PTDM.

287 deling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyr

288 In-hospital mortality rates in renal transplant recipients with STEMI are more favorabl

289 Among renal transplant recipients with STEMI, the use of reper

290 is of rejection rates and graft outcomes for renal transplant recipients with such preformed DSAs, de

291 Renal transplant recipients with suspicious masses or ca

292 receptor-activating antibodies (AT1R-Abs) in renal transplant recipients with vascular rejection and

293 withdrawal has been demonstrated in selected renal-transplant recipients with haematopoietic chimeris

294 latacept could be the treatment of choice in renal-transplant recipients with renal dysfunction attri

295 (PVAN) occurs in a significant percentage of renal transplant recipients, with BK virus reactivation

296 s were found in urine samples from 19 stable renal transplant recipients, with JCPyV quasispecies det

297 nce to recommend for or against screening of renal transplant recipients within 1 month, patients wit

298 We studied renal transplant recipients within an integrated healthc

299 urately detect graft artery abnormalities in renal transplant recipients without the risk of nephroto

300 nd the control group (n=100) was composed of renal transplant recipients without VL.